Patents by Inventor Janethe DE OLIVEIRA PENA

Janethe DE OLIVEIRA PENA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

ACTRII PROTEINS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH)

Publication number: 20230226146

Abstract: In some aspects, the disclosure relates to compositions and methods comprising ActRII polypeptides to treat, prevent, or reduce the progression rate and/or severity of pulmonary arterial hypertension, particularly treating, preventing or reducing the progression rate and/or severity of one or more pulmonary arterial hypertension associated complications.

Type: Application

Filed: June 22, 2021

Publication date: July 20, 2023

Inventors: Janethe de Oliveira Pena, Peter Linde, Sachindra Joshi, Gang Li, Patrick Andre, Ravindra Kumar
Method of identifying a subgroup of patients suffering from dcSSc which benefits from a treatment with sGC stimulators and sGC activators in a higher degree than a control group

Patent number: 11508483

Abstract: The present invention relates to a method of identifying a subgroup of patients suffering from diffuse cutaneous systemic sclerosis (dcSSc) which subgroup of patients benefits from a treatment with at least one sGC stimulator and/or sGC activator in a higher degree than patients not belonging to this subgroup.

Type: Grant

Filed: May 28, 2019

Date of Patent: November 22, 2022

Assignee: Adverio Pharma GmbH

Inventors: Peter Sandner, Melanie Hemmrich, Janethe De Oliveira Pena, Stephen Dawe
Method of Identifying a Subgroup of Patients Suffering from DcSSc which Benefits from a Treatment with sGC Stimulators and sGC Activators in a Higher Degree than a Control Group

Publication number: 20190371469

Abstract: The present invention relates to a method of identifying a subgroup of patients suffering from diffuse cutaneous systemic sclerosis (dcSSc) which subgroup of patients benefits from a treatment with at least one sGC stimulator and/or sGC activator in a higher degree than patients not belonging to this subgroup.

Type: Application

Filed: May 28, 2019

Publication date: December 5, 2019

Applicant: ADVERIO PHARMA GMBH

Inventors: Peter SANDNER, Melanie HEMMRICH, Janethe DE OLIVEIRA PENA, Stephen DAWE

ACTRII PROTEINS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH)

Method of identifying a subgroup of patients suffering from dcSSc which benefits from a treatment with sGC stimulators and sGC activators in a higher degree than a control group

Method of Identifying a Subgroup of Patients Suffering from DcSSc which Benefits from a Treatment with sGC Stimulators and sGC Activators in a Higher Degree than a Control Group